NSE filing, NSE: MOREPENLAB. Summary written from the filing by ALFA Finder's alert engine.
Morepen Laboratories Ltd: key numbers
- Share price
- ₹125.58
- Market cap
- ₹6,881 Cr
- Revenue (annual)
- ₹1,806 Cr
- Net profit (annual)
- ₹94.88 Cr
- P/E (TTM)
- 36.5×Sector 46.1×
- Promoter holding
- 35.65%+0.00% QoQ
- FII holding
- 3.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Morepen Laboratories Ltd
All →Morepen Laboratories Management Change
Morepen Laboratories announced promotions effective 27 October 2026 for two senior management personnel. Charanjeet Chitakara moves to Assistant Vice President (Quality Control) and Vivan Prashar to Vice President (Projects & Engineering).
Morepen Laboratories Other Announcement
Morepen filed its Q2FY27 Monitoring Agency Report confirming Nil deviation in QIP proceeds utilization. The company spent ₹1.12 crore on modernization and expansion during the quarter.
Morepen Laboratories Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs755 Cr (+81%), PAT Rs89 Cr (+117%), EBITDA margin 17.45% (+897bps). H1 revenue Rs1,330 Cr (+57%). CDMO scale-up drives mix.
Morepen Laboratories Results Update
Morepen hit record Q2 FY27 revenue up 81% and EBITDA up 273%, driven by CDMO scale-up. H1 EBITDA reached ₹220 Cr; API+CDMO capacity now 614 KL.
- API + CDMO manufacturing capacity
- 614 KL
Morepen Laboratories Q2 FY27 Results: Net Profit ₹88.9 Cr, Up 117.4% YoY
Morepen Laboratories Ltd reported revenue from operations of ₹746.5 Cr (+81.4% YoY) and net profit of ₹88.9 Cr (+117.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹88.9 Cr · +117.4% YoY
Morepen Laboratories Board Meeting Date
Morepen Laboratories Limited announced a board meeting scheduled for October 27, 2026. The meeting will consider and approve the financial results for the quarter ended September 30, 2026.
Other merger & restructuring announcements
All →Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr
Vraj Iron & Steel Merger & Restructuring Worth ₹4.55 Cr
Vraj Iron and Steel transferred 396,000 MVK Industries shares to promoter Gopal Sponge for Rs 4.55 Crore. The sale was completed on October 28, 2026.
- Value
- ₹4.55 Cr